A Look At Whether Ondas (ONDS) Is Undervalued After Recent Share Price Volatility

Advertisement

Context on recent Ondas share performance

Ondas (ONDS) has drawn attention after recent share price volatility, with the stock closing at US$9.31. Short term returns have been weak, including a 3.5% 1 day decline and a 20% slide over the past week.

See our latest analysis for Ondas.

Despite the recent pullback, with the 7 day share price return down almost 20%, Ondas still sits at US$9.31. This follows a period in which the 1 year total shareholder return has been very large and the 5 year total shareholder return stands at 19.82%, suggesting shorter term momentum is fading against a much stronger longer term picture.

If Ondas’s swings have you thinking about where else strong themes could emerge, this is a good moment to widen your search with the 34 power grid technology and infrastructure stocks

With the stock at US$9.31, a value score of 4, and an indicated intrinsic discount of about 53%, you now have to decide: is there a genuine buying opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 52.3% Undervalued

According to the most followed narrative on Ondas, a fair value of $19.50 sits well above the last close at $9.31, putting a spotlight on how that gap is justified.

By architecting what they call "Layered ISR," Ondas is effectively merging two worlds that used to operate in isolation. The foundation of this strategy is their recent ten-million-dollar investment in World View, a move that was less about diversifying their portfolio and more about buying the "high ground."

Read the complete narrative.

The fair value hinges on more than a story about drones and balloons. It incorporates expectations of rapid revenue expansion, improving profitability and a future earnings multiple that reflects the potential for this "Layered ISR" concept to scale into larger defense and border security contracts.

Result: Fair Value of $19.50 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this story can break quickly if defense customers scale back orders or if Ondas struggles to turn its current revenue growth into sustainable profitability.

Find out about the key risks to this Ondas narrative.

Next Steps

Given the mix of enthusiasm and concern around Ondas, this is a good time to move quickly, review the data yourself, and weigh both sides of the story. To see a concise breakdown of the main points investors are watching, including both potential upsides and key issues, take a look at the 4 key rewards and 4 important warning signs

Looking for more investment ideas?

If Ondas has sharpened your focus, do not stop there. Broaden your watchlist now with focused stock ideas that could suit very different investing goals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About NasdaqCM:ONDS

Ondas

Provides private wireless, drone, and automated data solutions in the United States and internationally.

Good value with adequate balance sheet.

Advertisement

Weekly Picks

LO
Lou_Basenese
OPTH logo
Lou_Basenese on Optimi Health ·

The Only Psychedelic Company Already Selling MDMA and Psilocybin to Real Patients, Yet Priced Like It Doesn’t Exist

Fair Value:US$1155.3% undervalued
49 users have followed this narrative
2 users have commented on this narrative
8 users have liked this narrative
WE
WealthAP
NOVO B logo
WealthAP on Novo Nordisk ·

Novo Nordisk (NVO): Is the "Easy Growth" Story Over?

Fair Value:DKK 407.7720.1% undervalued
69 users have followed this narrative
0 users have commented on this narrative
8 users have liked this narrative
VA
ValueInvestingSubstack
ZTS logo
ValueInvestingSubstack on Zoetis ·

Zoetis down -50% over the past year

Fair Value:US$92.9217.2% undervalued
23 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative
CE
CentryResearch
LEU logo
CentryResearch on Centrus Energy ·

Centrus Energy: The Next Nuclear Bottleneck Isn't Reactors. It's Fuel.

Fair Value:US$1907.4% undervalued
24 users have followed this narrative
0 users have commented on this narrative
10 users have liked this narrative

Updated Narratives

FE
PASS3 logo
FernandoLeal on Compass Gas e Energia ·

Compass Gas e Energia has a reliable dividend, with a consistent moat, high free cash flow margins and will expand to two digits net margin.

Fair Value:R$40.9439.5% undervalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
BR
Brunhilde_Wagner
CPRT logo
Brunhilde_Wagner on Copart ·

Compounder to Cash Generator in Real Time

Fair Value:US$2710.3% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
WI
WisetoWealth
PYPL logo
WisetoWealth on PayPal Holdings ·

The Underrated Transformation of a Digital Payments Giant

Fair Value:US$90.3137.9% undervalued
5 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

CU
MSFT logo
CubanEros on Microsoft ·

A wonderful business at reasonable price.

Fair Value:US$419.917.3% undervalued
84 users have followed this narrative
0 users have commented on this narrative
6 users have liked this narrative
OS
oscargarcia
NVDA logo
oscargarcia on NVIDIA ·

The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.

Fair Value:US$28029.8% undervalued
192 users have followed this narrative
9 users have commented on this narrative
15 users have liked this narrative
BE
PYPL logo
benjamin_lvieq on PayPal Holdings ·

PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback

Fair Value:US$6513.7% undervalued
72 users have followed this narrative
2 users have commented on this narrative
11 users have liked this narrative

Trending Discussion

DE
TDOC logo
derek_3wsdg on Teladoc Health ·

You’ve overlooked the activist investor factor. Travis Cocke’s Voss has announced 5% ownership through a 13G filing. They’ve added to that 5% since, and in doing so, have created a structural trap door for 27.42 Million Shares actively sold short. Chuck will announce lots of positives on July 29 but it’s what Voss announces shortly after that will rock the overextended Teledoc shorts. The Walmart partnership is the tip of the iceberg. The market is missing the sheer regulatory and enterprise friction of modern corporate healthcare. Teladoc isn't a "consumer app"; it is the primary digital infrastructure integrated directly into the legacy backends of Tier-1 insurance companies and fortune 500 employers, covering 105 million+ lives. Teladoc is acting as the digital top-of-funnel engine for the world's largest retailer. If Voss pushes the narrative that Teladoc is effectively the outsourced digital brain of Walmart's entire healthcare footprint, the fair value shifts from a basic health multiple to an enterprise distribution premium. Additionally , we are in a structural gold rush for high-quality, legally compliant, longitudinal medical data to train vertical healthcare AI models. Large technology hyperscalers and pharmaceutical giants cannot simply scrape the internet for this; they need structured clinical inputs. Teladoc sits on one of the largest de-identified virtual medical datasets on earth. From the activist playbook , we’ll see Voss demand the immediate creation of a Data & Diagnostics Licensing Division, transforming a legacy liability into an incredibly high-margin, pure-software data asset that requires zero human clinician hours to scale. Chuck is doing great work and deserves credi5 for the Teledoc turnaround but it will be Travis Cocke who will be responsible for a share price way beyond your $15 valuation.

1
|
0
AN
CSMG3 logo
andre_k1tsg on Companhia de Saneamento de Minas Gerais ·

Gostei

0
|
0